Comparative Pharmacology
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE versus METAHYDRIN.
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic